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Stroke prevention with oral anticoagulation (OAC) is central to the
modern management of atrial fibrillation (AF) patients.1 For many
years, vitamin K antagonists (VKAs, e.g. warfarin) have been the
default class of OAC, but we now recognize that it is not simply pre-
scribing VKA but very close attention to quality of anticoagulation
control is necessary, as reflected by the individual time in therapeutic
range (TTR).2 An average individual TTR of .70% is recommended
to maximize efficacy and safety of the VKAs.2,3
Nonetheless, the VKAs have significant inter- and intra-patient
variability, partly from diet and drug interactions, thus necessitating
regular international normalised ratio (INR) monitoring.2 More
recently, we have had the non-VKA oral anticoagulants (NOACs,
previously referred to as new or novel OACs4) available, which
offer efficacy, safety, and relative convenience compared with the
VKAs, for stroke prevention in AF.
Duetocostconsiderations, somehealthcare systemsmandatea ‘trial
of warfarin’ (sometimes called a ‘warfarin stress test’) for the initial
6 months, to determine whether a patient can do well on a VKA—
andonly if theTTR is suboptimal (e.g.,60%) is anNOACthen ‘author-
ized’ to be prescribed. When a patient is first started on a VKA, the
inception period is often associated with a poor TTR, and an excess
of thromboembolism has been noted in various studies.5,6
A major challenge therefore is to easily identify those AF patients
who are less likely to dowell on aVKA (with apoorTTR)whomaybe
best switched to anNOAC, rather than being exposed to suboptimal
TTRs and inadequate thromboprophylaxis, exposing the patient to
fatal and disabling strokes. Also, some healthcare settings have a
good track record of managing VKA very well, achieving (very) high
TTRs. Thus, rather than using guesswork (or budget considerations)
to decide between a VKA and an NOAC in a newly diagnosed
anticoagulation-naive patient, the SAMe-TT2R2 score was proposed
to aid such decision-making (Table 1).7
The SAMe-TT2R2 score is a relatively simple clinical risk score to
help decision-making in our everyday practice, whereby those
patients with a SAMe-TT2R2 score of 0–2 are on probability likely
to achieve a high TTR and thus, a VKA can be prescribed upfront.7
In contrast, a SAMe-TT2R2 score of .2 is associated with a poor
TTR, and aspatients are less likely todowell on aVKA(thus, exposing
them to more thromboembolism and bleeding), and intense efforts
to improve TTR by education8 or choosing an NOAC would be
better initial options.
In various independent cohorts, the SAMe-TT2R2 score has shown a
goodcapacity todiscriminatepatientswith a goodTTR(e.g..65–70%;
Table 2).9–11Moreover, the SAMe-TT2R2 score has proved to be valu-
able in predicting labile INRs, leading to both adverse bleeding and
thromboembolic events.10–12 Thus, robust evidence is accumulating
from large cohort studies of the value and clinical application of using
this simple score. Smaller, underpowered cohorts with only a narrow
rangeof INRs in thecohort studiedhaveshownless impressiveresults.13
The most recent validation study was published by Abumuaileq
et al.11 and demonstrated the ability of SAMe-TT2R2 score to identify
patients even with a high TTR cut-off point (≥70%), and since poor
TTR is related to more adverse effects, the score was also predictive
of all-causemortality and the composite endpoint of major bleeding,
thromboembolic complications, and mortality.11 Indeed, their data
are consistent with other prior studies from Italy,9 Spain,10 and
France.12 Thus, there is increasing evidence for the utility of the
SAMe-TT2R2 score, in helping the patient management pathway.
Of note, the SAMe-TT2R2 score is recommended in the UK
National Institute for Health and Care Excellence (NICE) NOAC
Implementation Collaborative consensus document (http://www.
nice.org.uk/guidance/cg180/resources) and also has been proposed
in the PRIMIS’ development of the Warfarin Patient Safety audit
tool (http://www.nottingham.ac.uk/primis/tools/audits/warfarin-
patient-safety.aspx). TheESCWorkingGrouponThrombosisAntic-
oagulation Task Force also recommends the use of SAMe-TT2R2
score to aid decision-making between a VKA and an NOAC, in a
newly diagnosed anticoagulation-naive patient with AF. A sug-
gested patient pathway for using the score in a newly diagnosed,
non-anticoagulated AF patient is shown in Figure 1.
With the NOACs, we cannot check INRs or the equivalent of a
parameter such as the TTR,14,15 and thus, we perhaps lose one
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powerful tool to predict anticoagulation quality in AF patients. Could
the SAMe-TT2R2 score achieve more beyond the prediction of TTR
cut-off points, perhaps by being a ‘TTR surrogate’ that informs the
clinical likelihood of achieving good quality anticoagulation control,
in a patient started on an NOAC? Further studies are needed to
test this hypothesis.
We can certainly encourage further observational studies planned
to evaluate the predictive power of SAMe-TT2R2 score, both in its
original and revised form, in predicting major bleeding and thrombo-
embolic complications, even beyondTTR assessment. A prospective
randomized trial, evaluating the impact of SAMe-TT2R2 score-guided
therapywithVKAorNOAC,would also allowus to formalize its clin-
ical utility, and is stated as a research recommendation in the 2014
NICE guidelines for AF.16 Ultimately, clinicians need simple clinical
tools to aid decision-making in everyday clinical practice, and not
rely on complex formulae based on multivariate models that were
derived from a specific selected population or a trial cohort. The
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Table 1 SAMe-TT2R2 score
Definitions Points
S Sex (female) 1
A Age (,60 years) 1
Me Medical historya 1
T Treatment (interacting drugs, e.g.
amiodarone for rhythm control)
1
T Tobacco use (within 2 years) 2
R Race (non-Caucasian) 2
Maximum
points
8
aMore than two of the following: hypertension, diabetes, coronary artery disease/
myocardial infarction, peripheral arterial disease, congestive heart failure, previous
stroke, pulmonary disease, and hepatic or renal disease.
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Table 2 SAMe-TT2R2 validation studies
Study design Patients Follow-up time SAMe-TT2R2 distribution
Apostolakis et al.7 Retrospective 1305 AF NA Score 0–1: 655 pts
Score 2: 303 pts
Score .2: 347 pts
Skov et al.13 Prospective 182 1 year Score 0–1: 105
Score ≥2: 77
Poli et al.9 Prospective 1089 AF 4.6 years (mean) Score 0–1: 624 pts
Score 2: 288 pts
Score .2: 177 pts
Gallego et al.10 Prospective 972 NVAF 952 days (median) Score 0–1: 431 pts
Score 2: 332 pts
Score .2: 208 pts
Lip et al.12 Prospective 8120 AF 1016 days (mean) Score 0–1: 4504 pts
Score 2: 2252 pts
Score .2: 1364 pts
AF, atrial fibrillation; NA, not applicable; NVAF, non-valvular atrial fibrillation; pts, patients.
Figure 1 Using the SAMe-TT2R2 score in a patient pathway. VKA, vitamin K antagonist; NOAC, non-VKA oral anticoagulant.
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SAMe-TT2R2 score may offer that clinical utility for us, rather than
relying on guesswork.
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